Tissue (biology)

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

Retrieved on: 
Thursday, February 2, 2023
Ketamine, Mental health, Peripheral nervous system, Vomiting, Food, PTSD, II, IND, Post-traumatic stress disorder, Tissue (biology), Nausea, Therapy, Drug discovery, Hallucination, Neck, Patient, Breakthrough therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Neuro, Toxicity, Pharmaceutical industry

The FDA has given guidance to Psycheceutical regarding its development plans for preclinical studies required for an IND submission and the design of related Phase I and II clinical studies.

Key Points: 
  • The FDA has given guidance to Psycheceutical regarding its development plans for preclinical studies required for an IND submission and the design of related Phase I and II clinical studies.
  • In 2023, Psycheceutical remains focused on completing the remaining IND-enabling studies that will support the IND submission and transition into Phase I and Phase II clinical studies.
  • "We are undergoing a mental health epidemic, with millions suffering from conditions like PTSD with no current therapeutics on the market to help.
  • We believe that NeuroDirect™ ketamine has the potential to be a life-altering treatment option that will provide profound benefits and relief to patients suffering from PTSD,” said Chad Harman, CEO of Psycheceutical.

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

Retrieved on: 
Thursday, January 26, 2023
Mental health, Ketamine, Peripheral nervous system, Vomiting, Suicide, PTSD, Post-traumatic stress disorder, Nausea, Tissue (biology), Speech disorder, Risk, OTC, United States Patent and Trademark Office, Hallucination, Depression, Neck, Patient, Patent, Anxiety, Lethargy, Hope, Neuro, Toxicity, Pain, Pharmaceutical industry

MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).

Key Points: 
  • MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).
  • The provisional patent application describes ketamine formulations for topical administration and related methods of treating PTSD, utilizing NeuroDirect™ non-systemic drug delivery technology.
  • These novel ketamine formulations, and methods of treatment, are being developed to reduce the side effects caused by prior formulations, such as hallucinations, nausea, lethargy, and toxicity, but more importantly to also reduce pain and symptoms of PTSD.
  • “PTSD can be a serious mental health disorder, with no known effective therapeutic solutions currently available.

World Orphan Drug Alliance Announces Agreement with Theratechnologies for the Distribution of EGRIFTA SV

Retrieved on: 
Thursday, January 5, 2023
CEE, WODA, HIV, Degenerative disease, LATAM, Lipodystrophy, Tissue (biology), MENAT, Central and Eastern Europe, Pharmaceutical industry, Airline, Medis

Under the agreement, the World Orphan Drug Alliance (WODA) has obtained exclusive distribution rights to EGRIFTA SV® (tesamorelin for injection) to be made available under a Named Patient Program.

Key Points: 
  • Under the agreement, the World Orphan Drug Alliance (WODA) has obtained exclusive distribution rights to EGRIFTA SV® (tesamorelin for injection) to be made available under a Named Patient Program.
  • The multi-territorial agreement covers 41 countries in the regions of Latin America (LATAM), Middle East, North Africa & Turkey (MENAT) and Central & Eastern Europe (CEE).
  • DUBAI, United Arab Emirates and SÃO PAULO, Brazil and LJUBLJANA, Slovenia, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors focused on providing access to treatments for rare diseases and specialty medicines in complex and underserved markets around the world, today announced a long-term, multi-territorial distribution agreement with Theratechnologies Inc. ("Theratechnologies") for EGRIFTA SV® in 41 countries.
  • "We are excited to partner with Theratechnologies and support them in addressing markets outside of North America.

Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation

Retrieved on: 
Monday, December 19, 2022
Tissue (biology), Mastectomy, Breast, Risk, Breast cancer, Rose Parade, Quality of life, Life, BRI, Donate Life America, Hypoesthesia, Nerve, Woman, Medical imaging, AxoGen

This is the tenth year Axogen has co-sponsored the Donate Life float to help raise awareness for the importance of organ and tissue donation.

Key Points: 
  • This is the tenth year Axogen has co-sponsored the Donate Life float to help raise awareness for the importance of organ and tissue donation.
  • During a mastectomy, the nerves that provide feeling to a patient’s breasts are cut when the breast tissue is removed.
  • Madelyn (Madie) Nicpon was also an Avance Nerve Graft recipient whose life was improved by the gift of nerve tissue donation.
  • In 2019, Madie rode on the Donate Life Float during the Rose Parade.

New Study Indicates Almonds Improve Some Appetite-Regulating Hormones in Overweight/Obese Adults

Retrieved on: 
Monday, December 5, 2022
Overweight, Hormone, Peptide YY, Vitamin E, Almond, Coates, Potassium, Human nutrition, Perception, Nutrient, Ageing, Tissue (biology), Glucagon, Insulin resistance, Public health, Research, Pinterest, YY, Hunger, European Journal of Nutrition, Randomized controlled trial, Meta-analysis, Weight gain, Appetite, Body mass index, Cardiovascular disease, Eating, Diabetes, Ghrelin, Magnesium, Obesity, Weight loss, Snack, DV, University of South Australia, COVID-19, Boredom, Pancreatic polypeptide, Risk, Diet, Degenerative disease, United States Department of Agriculture, University, Energy, Human, Leptin, Farmer, Systematic review, BMI, Federal, Cholecystokinin, Birth control, Milk, Dietary supplement, Soft drink, Nutrition, Exercise, Agriculture

MODESTO, Calif., Dec. 5, 2022 /PRNewswire/ -- Appetite regulation and weight management are complex. People eat not only for hunger, but for a variety of other reasons, such as stress, boredom, excitement, and so much more, which can lead to overweight/obesity. Addressing the challenge of overweight/obesity requires a multifaceted approach with innovative thinking, and new research about almonds is doing just that. A study comprising adults with overweight and obesity showed almond consumption helped improve crucial appetite-regulating hormones.1

Key Points: 
  • A study comprising adults with overweight and obesity showed almond consumption helped improve crucial appetite-regulating hormones.1
    The rates of overweight and obesity are a growing public health concern.
  • Dr. Alison Coates and her collaborators studied how almonds affected appetite, including the hormones that help regulate appetite.
  • Our understanding of almonds is evolving as nutrition researchers apply the scientific method to explore these important topics.
  • In her research, Dr. Coates hypothesized that almonds would have a favorable effect on the hormones that regulate appetite, as well as impact the study participants' perception of their appetites.

Noster Microbiome Research: Potential obesity-reducing food supplement

Retrieved on: 
Tuesday, November 1, 2022
Body mass index, Overnutrition, Consumption, Health, The Progress of Medicine in the Philippines, Mouse, Insulin resistance, Water, Obesity, Exercise, BMI, Research, Capsule, Diet, Risk, Comparison, Degenerative disease, Person, Kidney failure, Human, Tissue (biology), Linoleic acid, Food, Stroke, HYA, Insulin, Diabetes, Diagnosis, Meal, Dietary supplement, Soft drink, Medicine

The consumption of the substance in the form of food supplements may therefore reduce the risk of obesity-related health disorders.

Key Points: 
  • The consumption of the substance in the form of food supplements may therefore reduce the risk of obesity-related health disorders.
  • Their results suggest that the consumption of HYA-containing food reduces visceral fat.
  • During a period of 12 weeks, 28 subjects were given 'test food', 50% of which consisted of HYA.
  • Effects of Consumption of HYAcontaining Food on the Visceral Fat Area in Healthy Subjects, Prog.

Noster Microbiome Research: Potential obesity-reducing food supplement

Retrieved on: 
Tuesday, November 1, 2022
Body mass index, Overnutrition, Consumption, Health, The Progress of Medicine in the Philippines, Mouse, Insulin resistance, Water, Obesity, Exercise, BMI, Research, Capsule, Diet, Risk, Comparison, Degenerative disease, Person, Kidney failure, Human, Tissue (biology), Linoleic acid, Food, Stroke, HYA, Insulin, Diabetes, Diagnosis, Meal, Dietary supplement, Soft drink, Medicine

The consumption of the substance in the form of food supplements may therefore reduce the risk of obesity-related health disorders.

Key Points: 
  • The consumption of the substance in the form of food supplements may therefore reduce the risk of obesity-related health disorders.
  • Their results suggest that the consumption of HYA-containing food reduces visceral fat.
  • During a period of 12 weeks, 28 subjects were given 'test food', 50% of which consisted of HYA.
  • Effects of Consumption of HYAcontaining Food on the Visceral Fat Area in Healthy Subjects, Prog.

Global Stromal Vascular Fraction Market Research Report 2022 - Surging Demand for Aesthetic & Reconstructive Therapies Enhances Market Prospects - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Health, Cardiology, Transfer, Tissue (biology), CAGR, Growth, COVID-19, Pet

The "Stromal Vascular Fraction - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stromal Vascular Fraction - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Isolation Products, one of the segments analyzed in the report, is projected to record a 4% CAGR and reach US$79.3 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $27.2 Million, While China is Forecast to Grow at 5.5% CAGR
    The Stromal Vascular Fraction market in the U.S. is estimated at US$27.2 Million in the year 2020.
  • In the global Transfer Products segment, USA, Canada, Japan, China and Europe will drive the 4.5% CAGR estimated for this segment.

Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE, a Phase 2 Clinical Trial of SPI-62 for Cushing’s Syndrome

Retrieved on: 
Wednesday, September 28, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Adenoma, Autoimmunity, Rheumatology, Safety, CRH, Steroid, Brain, MD, Glaucoma, European Medicines Agency, Depression, Hypertension, ACTH, Diabetes, Endocrinology, Patient, Osteopenia, Liver disease, Disease, Pain, Bone loss, Dyslipidemia, Female, Male, Medication, Liver, Doctor of Philosophy, Adrenocorticotropic hormone, Tissue, Diagnosis, Glucocorticoid, Sleep, Muscle, Tissue (biology), SME, Mortality, Adipose tissue, EMA, Hyperglycemia, Pharmaceutical industry, EU, Sparrow

This study is one of three phase 2 trials planned to investigate SPI-62 as a treatment for disorders of glucocorticoid excess.

Key Points: 
  • This study is one of three phase 2 trials planned to investigate SPI-62 as a treatment for disorders of glucocorticoid excess.
  • Dosing our first patient in this phase 2 trial is an important milestone in our clinical development process of SPI-62, said Frank Czerwiec, MD, PhD, Chief Medical Officer of Sparrow.
  • Cushings is a devastating rare disease with debilitating morbidities such as depression, bone loss, and diabetes, and if left untreated, high levels of mortality.
  • The primary endpoint is to determine the pharmacologic effects of SPI-62 in patients with adrenocorticotropic hormone (ACTH)-dependent Cushings syndrome.

Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica

Retrieved on: 
Friday, September 9, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cardiovascular disease, Osteocalcin, Insulin resistance, Osteoporosis, Patient, PMR, Polymyalgia rheumatica, Steroid, Dyslipidemia, Autoimmune disease, Vasculitis, Autoimmunity, Doctor of Philosophy, Toxicity, Rheumatology, Disease, Giant cell arteritis, Medication, C-reactive protein, Tissue, Pains, NCT, Glaucoma, Bruise, Endocrinology, Glucocorticoid, Skin, ACHES, Weight gain, Tissue (biology), Cortisone, Stroke, Hypertension, Aortic aneurysm, Bone loss, GCA, Myalgia, Risk, Motion, Diabetes, Insomnia, Muscle atrophy, Life, Degenerative disease, Prednisolone, Pharmaceutical industry, Dietary supplement

This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.

Key Points: 
  • This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.
  • If we observe separation of the desired from undesired effects of prednisolone, well be an important step closer to solving a decades-old puzzle in autoimmune disease treatment.
  • Patients with PMR taking a daily 10mg oral dose of prednisolone may be eligible for the trial.
  • To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .